Nu Skin Enterprises Inc (Nu Skin) is an integrated beauty and wellness company that operates through a direct selling channel. The company's product categories include beauty and wellness products. Nu Skin's beauty brand include the ageLOC LumiSpa iO and ageLOC WellSpa iO, which are connected devices providing personalized consumer experiences. The wellness brand, Pharmanex, offers nutritional products, while the ageLOC brand offers anti-aging solutions across both beauty and wellness categories. It generates revenue from two brands, Nu Skin and Rhyz. In FY2025, it generated 85% of its revenue Nu Skin brand and remaining 15% from Rhyz brand.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

R&D arm of the company focuses on development and markets of innovative products by leveraging the disciplines of science, technology, and sourcing. The company initiatives include global consumer research to identify needs and insights, internal research and product development, clinical validation, regulatory due diligence, quality testing, joint research projects, collaborations, clinical studies, and the identification and assessment of technologies for potential licensing arrangements. It collaborates with researchers from universities and other research institutions globally and invests in acquisitions to supplement research capabilities and acquire technologies. The R&D units are in Provo, Utah, and Shanghai, China. In FY2025, the company incurred expenses of US$10.8 million on its R&D, which as a percentage of revenue, stood at 0.7%.